These findings collectively indicate that by enhancing the infiltration and activation of NK and CD8+ T cells, Tri-NAb mediates efficient melanoma regression, suggesting its universal potential as an excellent antitumor therapy. The gene discussed is CD8A; the disease is melanoma.